Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients

被引:2
|
作者
van der Lee, Manon [1 ]
Sankatsing, Roaj
Schippers, Emile
Vogel, Martin
Faetkenheuer, Erd
van der Ven, Andre
Kroon, Frank
Rockstroh, Juegen
Wyen, Christoph
Baeumer, Anselm
de Root, Eric
Koopmans, Peter
Stroes, Erik
Reiss, Peter
Burger, David
机构
[1] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands
[2] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands
[3] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
[4] Univ Med Ctr Leiden, Dept Infect Dis, Leiden, Netherlands
[5] Univ Bonn, Dept Internal Med 1, D-5300 Bonn, Germany
[6] Univ Cologne, Dept Internal Med, Cologne, Germany
[7] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands
[8] Acad Med Ctr, Dept Infect Dis Trop Med & Aids, Amsterdam, Netherlands
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Lopinavir/ritonavir-containing antiretroviral therapy can cause hyperlipidaemia. However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin undergoes minimal metabolism by CYP450, so no CYP450-based interaction with lopinavir/ritonavir is expected. This study explored the lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin and vice versa. Methods: HIV-infected patients on lopinavir/ritonavir (viral load > 400 copies/ml) with total cholesterol (TC) > 6.2 mmol/l were treated with rosuvastatin for 12 weeks, starting on 10 ring once daily. If fasting target values (TC < 5.0 mmol/l, high-density lipoprotein-cholesterol > 1.0 mmol/l, low-density lipoprotein- cholesterol [LDL-c] < 2.6 mmol/l and triglycerides < 2.0 mmol/1) were not reached, rosuvastatin was escalated to 20 mg or 40 mg at week 4 and 8, respectively. Plasma lopinavir/ritonavir trough levels (C-min) were determined at week 0, 4, 8 and 12 and rosuvastatin C-min, at week 4, 8 and 12. Results: Twenty-two patients completed the study. Mean reductions in TC and LDL-c from baseline to week 4 (on rosuvastatin 10 mg once a day) were 27.6% and 31.8%, respectively. Lopinavir/ritonavir concentrations were not influenced by rosuvastatin (P=0.44 and 0.26, repeated-measures analysis). Median (interquartile range) rosuvastatin C-min, for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively. Conclusions: Rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, but rosuvastatin levels unexpectedly appeared to be increased 1.6-fold compared with data from healthy volunteers. Until safety and efficacy have been confirmed in larger studies, the combination of rosuvastatin and lopinavir/ritonavir should be used with caution.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 50 条
  • [1] Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
    Lopez Aspiroz, Elena
    Santos Buelga, Dolores
    Cabrera Figueroa, Salvador
    Lopez Galera, Rosa Maria
    Ribera Pascuet, Esteban
    Dominguez-Gil Hurle, Alfonso
    Garcia Sanchez, Maria Jose
    THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 573 - 582
  • [2] Toxicogenetics of lopinavir/ritonavir in HIV-infected European patients
    Lopez Aspiroz, Elena
    Cabrera Figueroa, Salvador Enrique
    Cruz, Raquel
    Porras Hurtado, Gloria Liliana
    Fuertes Martin, Aurelio
    Dominguez-Gil Hurle, Alfonso
    Carracedo, Angel
    PERSONALIZED MEDICINE, 2014, 11 (03) : 263 - 272
  • [3] Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Waters, Laura J.
    Moyle, Graeme
    Bonora, Stefano
    D'Avolio, Antonio
    Else, Laura
    Mandalia, Sundhiya
    Pozniak, Anton
    Nelson, Mark
    Gazzard, Brian
    Back, David
    Boffito, Marta
    ANTIVIRAL THERAPY, 2007, 12 (05) : 825 - 830
  • [4] The Effect of Acid Reduction With a Proton Pump Inhibitor on the Pharmacokinetics of Lopinavir or Ritonavir in HIV-Infected Patients on Lopinavir/Ritonavir-Based Therapy
    Overton, Edgar T.
    Tschampa, Jean M.
    Klebert, Michael
    Royal, Mike
    Rodriguez, Mark
    Spitz, Teresa
    Kim, GeYoul
    Mondy, Kristin E.
    Acosta, Edward P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1050 - 1055
  • [5] Sex Differences in Lopinavir and Ritonavir Pharmacokinetics Among HIV-Infected Women and Men
    Umeh, Obi C.
    Currier, Judith S.
    Park, Jeong-Gun
    Cramer, Yoninah
    Hermes, Ashwaq E.
    Fletcher, Courtney V.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (12): : 1665 - 1673
  • [6] The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis
    Gupta, Samir K.
    Rosenkranz, Susan L.
    Cramer, Yoninah S.
    Koletar, Susan L.
    Szczech, Lynda A.
    Amorosa, Valerianna
    Hall, Stephen D.
    AIDS, 2008, 22 (15) : 1919 - 1927
  • [7] Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir
    de Kanter, Clara T. M. M.
    Keuter, Monique
    van der Lee, Manon J.
    Koopmans, Peter P.
    Burger, David M.
    ANTIVIRAL THERAPY, 2011, 16 (03) : 435 - 437
  • [8] Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets
    Decloedt, Eric H.
    McIlleron, Helen
    Smith, Peter
    Merry, Concepta
    Orrell, Catherine
    Maartens, Gary
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) : 3195 - 3200
  • [9] Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients
    Chiu, Yi-Lin
    Klein, Cheri E.
    Woodward, William C.
    King, Kathryn R.
    Naylor, Christian
    Awni, Walid
    Brun, Scott
    AIDS PATIENT CARE AND STDS, 2007, 21 (04) : 247 - 251
  • [10] Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients
    Ramautarsing, Reshmie A.
    van der Lugt, Jasper
    Gorowara, Meena
    Sophonphan, Jiratchaya
    Ananworanich, Jintanat
    Lange, Joep M. A.
    Burger, David M.
    Phanuphak, Praphan
    Ruxthungtham, Kiat
    Avihingsanon, Anchalee
    ANTIVIRAL THERAPY, 2013, 18 (02) : 249 - 252